Dinesh Patel, Protagonist Therapeutics CEO
October 11, 2021 11:12 AM EDT
FDA+

In quick turn­around, FDA lifts full clin­i­cal hold on Pro­tag­o­nist's blood can­cer pro­gram

Max Gelman

Senior Editor

Not even a month af­ter be­ing slapped with a full clin­i­cal hold on all stud­ies re­lat­ed to a blood can­cer pro­gram, Pro­tag­o­nist Ther­a­peu­tics saw reg­u­la­tors …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times